The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: objective Growth hormone replacement therapy in GH‐deficient children is associated with enhanced adrenal androgen production, raising the possibility that GH might stimulate adrenocortical hormone secretion. This has not been extensively investigated in adults to date. GH is a potent modulator of the activity of the 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) enzyme and by altering cortisol metabolism can affect the function of the hypothalamo–pituitary–adrenal (HPA) axis and therefore potentially of adrenal androgen secretion. This study examined the effects of GH replacement in GH‐deficient adults on adrenal androgen secretion. design Prospective study of the effect of GH replacement therapy on adrenal androgen production in patients with adult onset hypopituitarism over a 12‐month period. patients and methods Thirty adult GH‐deficient patients were classified into two groups according to their cortisol responses to an insulin‐induced hypoglycaemia or a glucagon stimulation test: 13 patients were adrenocorticotropic hormone (ACTH)‐sufficient (nine females, age 45·1 ± 3 years), whereas 17 patients were ACTH‐deficient (11 females, age 45·5 ± 3 years). Serum samples were collected before patients were initiated on GH replacement therapy using a dose titration regimen, and after 6 and 12 months on GH therapy for measurement of serum IGF‐I, dehydroepiand‐rosterone sulphate (DHEAS), Δ4‐Androstenedione (A4), testosterone, cortisol, sex hormone binding globulin (SHBG) and cortisol binding globulin (CBG). results Six months after the initiation of GH replacement therapy, serum IGF‐I levels were within the normal age‐related reference range in both groups of patients and this was maintained at 12 months [in all patients 0 vs. 6 months: median (interquartile range): 92·5 ng/ml (73–116 ng/ml) vs. 191 ng/ml (159–224 ng/ml), P < 0·01]. In both ACTH‐sufficient and ‐deficient groups of GH‐deficient patients, pretreatment serum DHEAS levels were lower than the normal age‐related reference range (P < 0·01); the ACTH‐deficient patients had significantly lower DHEAS levels than the ACTH‐sufficient patients [median (interquartile range): 0·5 µmol/l (0·4–1·2 µmol/l) vs. 1·5 µmol/l (0·6–2·7 µmol/l), P < 0·05]. Following GH replacement therapy, median levels of serum DHEAS levels rose from 1·5 µmol/l (0·6–2·7 µmol/l) to 1·9 µmol/l (1·9–3·9 µmol/l) in ACTH‐sufficient patients, increasing in 11 of the 13 patients (P < 0·02). In this group, the median percentage increase from baseline was 32% at 6 months (P < 0·05). In contrast, baseline serum DHEAS levels [0·5 µmol/l (0·4–1·2 µmol/l)] declined in or from the measurable range in 47% of ACTH‐deficient patients [median −16%; range −36–0] and only in one patient a + 0·2 µmol/l increase was observed. GH dose requirements tended to be lower in ACTH‐sufficient patients [1·2 U/day (0·8–1·4 U/day) vs. 1·6 U/day (1·0–2·0 U/day); P = 0·062]. There were no significant changes in serum testosterone, A4, SHBG and/or CBG levels, compared to the pretreatment levels, in either group of patients over the 12 months of GH replacement. conclusions This study shows that median serum DHEAS levels are significantly lower in GH‐deficient patients, even those with intact ACTH reserve, than in aged‐matched controls. GH replacement therapy is associated with a significant increase in mean serum DHEAS only in ACTH‐sufficient patients. These findings are consistent with either (i) GH stimulation of adrenal androgen production in the permissive presence of ACTH or (ii) an inhibitory effect of GH on 11β‐HSD type 1 activity leading to enhanced cortisol clearance, subsequent activation of the HPA axis and ACTH‐mediated androgen secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morales, A. J., Haubrich, R. H., Hwang, J. Y., Asakura, H., & Yen, S. S. C. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00507.x · Cited by 418
Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man
Palermo, M., Shackleton, C. H. L., Mantero, F., & Stewart, P. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00853.x · Cited by 276 · cited 1×
“We and others have demonstrated previously that cortisol metabolism is enhanced by GH through an inhibition of the 11β-HSD type 1 enzyme (Weaver et al., 1994; Palermo et al., 1996; Gelding et al., 1998; Walker et al., 1998; Moore et al., 1999).”
Background5 α-reductase activity in polycystic ovary syndrome
Stewart, P. M., Edwards, C. R. W., Shackleton, C. H. L., & Beastall, G. H. (1990) · The Lancet · doi:10.1016/0140-6736(90)90664-q · Cited by 189 · cited 2×
“This modulation of glucocorticoid metabolism and secondary augmentation of ACTH flux has also been implicated in the hyperandrogenesim of polycystic ovarian syndrome (Stewart et al., 1990; Rodin et al., 1994).”
BackgroundSpan, J. P. T., Pieters, G. F. F. M., Sweep, C. G. J., Hermus, A. R. M. M., & Smals, A. G. H. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6463 · Cited by 132 · cited 1×
“Our results, obtained in GH-deficient subjects, indicate that a direct effect on IGF-I generation may also be involved, probably mediated by androgenic activity (Span et al., 2000).”
ResultGelding, S. V., Taylor, N. F., Wood, P. J., Noonan, K., Weaver, J. U., Wood, D. F., & Monson, J. P. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.3641180.x · Cited by 124
Self-citation
Cited by
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321
Self-citationModulation of glucocorticoid metabolism by the growth hormone – IGF‐1 axis
Agha, A., & Monson, J. P. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02763.x · Cited by 108
Self-citationGiavoli, C., Libé, R., Corbetta, S., Ferrante, E., Lania, A., Arosio, M., Spada, A., & Beck-Peccoz, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1114 · Cited by 97
van Thiel, S. W., Romijn, J. A., Pereira, A. M., Biermasz, N. R., Roelfsema, F., van Hemert, A., Ballieux, B., & Smit, J. W. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1802 · Cited by 66
Metadata
- Authors
- Isidori, A. M., Kaltsas, G. A., Perry, L., Burrin, J. M., Besser, G. M., & Monson, J. P.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2003-04-17
- Volume
- 58
- Issue
- 5
- Pages
- 601-611
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2154511192
- Cited by
- 34
- References
- 5
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism. https://app.cochat.ai/papers/10.1046/j.1365-2265.2003.01759.x
- The paper
- Isidori, A. M., Kaltsas, G. A., Perry, L., Burrin, J. M., Besser, G. M., & Monson, J. P. (2003). The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2003.01759.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.